Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Bupropion Hydrochloride

These articles are all highly relevant Bupropion Hydrochloride. I believe this information can help you understand Bupropion Hydrochloride's professional information. If you want to know more, you can contact us at any time, we can provide you with more professional guidance.
  • Drug Patent & Exclusivity Expiration Report - Week of Aug 18 2025

    Drug Patent & Exclusivity Expiration Report - Week of Aug 18 2025

    2025-08-18

    This week, there are 10 drugs in the patent and exclusivity list. They are: - SPRINGWORKS THERAPEUTICS INC's OGSIVEO, containing active ingredient NIROGACESTAT HYDROBROMIDE - VERO BIOTECH INC's GENOSYL, containing active ingredient NITRIC OXIDE - CURRAX PHARMACEUTICALS LLC's ONZETRA XSAIL, containing active ingredient SUMATRIPTAN SUCCINATE - SANDOZ INC's QOLIANA, containing active ingredient BRIMONIDINE TARTRATE - UNITED THERAPEUTICS CORP's TYVASO DPI, containing active ingredient TREPROSTINIL - CUMBERLAND PHARMACEUTICALS INC's ACETADOTE, containing active ingredient ACETYLCYSTEINE - AXSOME THERAPEUTICS INC's AUVELITY, containing active ingredient BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - BIOCODEX SA's DIACOMIT, containing active ingredient STIRIPENTOL - PHARMACYCLICS LLC's IMBRUVICA, containing active ingredient IBRUTINIB - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JARDIANCE, containing active ingredient EMPAGLIFLOZIN Read More